BioMedNewsBreaks Archive - Page 103 of 255

TuesdayOct 24, 2023 12:10 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. The segment focuses on the company’s most recent announcement of its topline results from the CLEAR Mind phase 2a clinical trial of LGVN’s Lomecel-B(TM) for the treatment of mild Alzheimer's disease. According to the segment, the Lomecel-B study met its primary safety endpoint and is supported by lack of deterioration in cognitive or atrophy signals. The encouraging results will be used as a foundation…

MondayOct 23, 2023 12:11 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Filing in Connection with Proposed Arrangement with Celly Nu

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions. Together with Celly Nutrition Corp. (“Celly Nu”), FSD Pharma today announced its filing on www.SEDARPlus.ca its management information circular and related materials in connection with the special meeting of FSD Pharma Securityholders (as defined in the company’s press release dated Oct. 5, 2023). The meeting, to be held virtually on Nov. 20, 2023, at 1:00 p.m. (Toronto time) through the AGM Connect meeting platform, is to approve, among other things, the previously-announced plan of arrangement under which…

FridayOct 20, 2023 2:53 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced rapid enrollment in its potentially pivotal study involving its flagship drug candidate, Berubicin, and is moving closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”). “The Texas-based company has clinical trial sites operating in the U.S., Italy, France, Spain, and Switzerland, to evaluate Berubicin’s performance against standard of care alkylating chemotherapy agent Lomustine for treating recurrent GBM. GBM has been generally untreatable by anthracyclines because of their inability to cross the blood-brain barrier, but Berubicin is believed to be able to cross the…

FridayOct 20, 2023 2:28 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Participating in Webinar Focused on Future Health Tech

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, will be spotlighted in webinar taking place today. The webinar is scheduled to start at 3 p.m. ET. Renovaro BioSciences CEO Mark Dybul will be featured in the webinar, which is titled “Future Health Tech: Challenges and Opportunities,” and will provide key information about the company and its role as a leader in the health tech space. Those interested in joining the webinar can call in by dialing 1-507-473-4847 in the United States, then use…

ThursdayOct 19, 2023 3:02 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured at this month’s Virtual Investor Ask the CEO Conference. CNS Pharmaceuticals CEO John Climaco is scheduled to participate in a live moderated webcast during the conference; the webcast is slated to start at 4 p.m. ET. The distinctive conference provides a unique opportunity for members of the investment community to ask questions directly to leaders of specific companies during the live event. According to the announcement, executive answer as many questions…

ThursdayOct 19, 2023 12:34 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Spotlighted in Latest Episode of Bell2Bell Podcast

PaxMedica (NASDAQ: PXMD), a prominent clinical-stage biopharmaceutical company, was featured in the most recent release of the Bell2Bell podcast series. During the segment, PaxMedia CEO and chair Howard Weisman and PaxMedica corporate communications representative Buzz Woods provided an overview of the company’s latest accomplishments and future objectives with Bell2Bell host Stuart Smith. The trio discussed PaxMedia’s pioneering work in novel anti-purinergic drug therapies (“APT”) for neurologic conditions, specifically autism spectrum disorder (“ASD”) along with the company’s initiatives and visionary advancements in the novel APT therapies space. The Bell2Bell Podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread…

WednesdayOct 18, 2023 1:33 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Featured in Bell2Bell Podcast

PaxMedica (NASDAQ: PXMD), a prominent clinical-stage biopharmaceutical firm, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica’s CEO and Chairman Howard Weisman and Buzz Woods, from the company’s corporate communications department, joined the program to offer a compelling overview of the company’s recent achievements and future objectives. During the podcast, Weisman and Woods share insights into the company’s groundbreaking work in novel anti-purinergic drug therapies (“APT”) for neurologic conditions, primarily autism spectrum disorder (“ASD”). They discuss perspectives on PaxMedica’s initiatives and visionary advancements…

WednesdayOct 18, 2023 9:53 am

BioMedNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthen Position in Alternative Mental-Health Treatments Sector

Lucy Scientific Discovery (NASDAQ: LSDI), a pioneer in alternative mental-health treatments, is working to provide ingredients for effective mental-health treatment and therapies, including psilocybin and MDMA. According to a recent article spotlighting LSDI, the company is “well positioned” to support the mental-health space as it continues to grow. The article noted that mental-health issues are impacting millions of Americans a year and that treatments are finally evolving to treat these issues. Prescriptions for selective serotonin reuptake inhibitors (“SSRIs”) have long been a mainstay in the industry, but they don’t work for everyone and often have debilitating side effects. The article…

TuesdayOct 17, 2023 11:44 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, announced that it has innovated its investigational drug, CNM-Au8(R), with nanotechnology. Clene is evaluating CNM-Au8(R) for the treatment of neurodegenerative disease, and the innovation reflects the growing importance of nanotechnology in the drug space. The announcement noted that Clene’s nanotechnological approach was recently awarded a substantial grant by the National Institute of Neurological Disorders and Stroke (“NINDS”) of the National Institutes of Health (“NIH”) to conduct an Expanded Access Protocol in ALS. The announcement also noted that Clene is…

MondayOct 16, 2023 12:37 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in a recent article focused on glioblastoma, the most aggressive type of brain cancer. Noting that glioblastoma has an average survival of only 14 to 16 months after diagnosis, the article points out that currently, glioblastoma has no cure and, because it is a highly invasive tumor, complete surgical removal is difficult. “Even with aggressive treatment, the cancer tends to recur, leading to a grim prognosis,” the article states. “The high mortality rate of…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Filing in Connection with Proposed Arrangement with Celly Nu

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Participating in Webinar Focused on Future Health Tech

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Spotlighted in Latest Episode of Bell2Bell Podcast

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Featured in Bell2Bell Podcast

BioMedNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthen Position in Alternative Mental-Health Treatments Sector

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search